Osseointegration in arthroplasty: can simvastatin promote bone response to implants?
Cementless fixation depends on bone ingrowth for long-term success. Simvastatin as a lipid lowering agent has been demonstrated to have osteoanabolic effects. This study was designed to measure the possible effect of simvastatin on implant osseointegration. Bilateral femoral implantation of titanium cylinders was performed in 20 rabbits. Blood lipid levels were measured pre- and postoperatively. Scanning electron microscopy (SEM) was used to measure the percentage of the surface of each implant in contact with bone and mechanical pull-out testing was performed. The blood lipid levels were significantly reduced in the simvastatin group. Histomorphometric examination revealed increased bone ingrowth and mechanical examination showed increased interface strength in the simvastatin group. Mechanical and histological data showed superior stability and osseous adaptation at the bone/implant interface for the simvastatin group. We conclude that simvastatin has potential as a means of enhancing bone ingrowth, which is a key factor in the longevity of cementless implants.
D000818:Animals; D019643:Arthroplasty, Replacement / Q000379:methods*; D005269:Femur / Q000187:drug effects / Q000648:ultrastructure; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D020007:Implants, Experimental; D008055:Lipids / Q000097:blood; D008297:Male; D008422:Materials Testing / Q000379:methods*; D008855:Microscopy, Electron, Scanning; D023421:Models, Animal; D016348:Osseointegration / Q000187:drug effects* / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D011817:Rabbits; D019821:Simvastatin / Q000494:pharmacology*
D000960:Hypolipidemic Agents; D008055:Lipids; D019821:Simvastatin